Participated · Equity · Apr 2026

Founded in March 2023, Shengshu Technology builds foundational or "world" models across three areas: multimodal generation, real-time interaction, and physical-world actions. Its Vidu Q model targets professional video and content production use cases in comics, advertising, e-commerce, and film. The Vidu S1 model enables voice-controlled video generation at 540P and 25FPS while running efficiently on consumer-grade graphics cards. In December 2025 the company open-sourced Motus, presented as a unified world model for perception, prediction, and action, and its Motubrain robot control model reached a 95.8% success rate on the RoboTwin 2.0 benchmark. The company announced a $500 million funding round to support continued model research and technological innovation.

Participated · Equity · Mar 2026

Earendil Labs applies AI across discovery, design, optimization, and development to generate and progress protein-based biologics programs. Its AI-native platform has produced more than 40 programs and includes HXN-1001, a half-life extended anti-TL1A antibody that the company says is ready for Phase 2 clinical development, with multiple IND submissions planned in 2026 and 2027. The company works through a combination of internal pipeline development and strategic partnerships, including a 2025 worldwide exclusive license agreement and broader strategic collaboration with Sanofi covering multiple programs. Earendil operates alongside affiliate Helixon Therapeutics and targets therapies for autoimmune diseases, cancer, and other areas of unmet medical need. With the announced $787 million financing, the company plans to scale its AI-driven R&D organization, expand scientific and engineering teams, and advance multiple internal programs toward clinical milestones.

Participated · Series A · Aug 2021

Ellipsis Health is a San Francisco, CA–based AI healthcare technology company that developed Sage, an emotionally intelligent AI voice agent for care management and behavioral health monitoring. Sage is powered by the company’s patented Empathy Engine and is designed to expand provider capacity, streamline workflows, and elevate patient engagement. The company serves leading healthcare providers and payers, focusing on patients with complex physical, behavioral, and social needs that drive the majority of healthcare costs. Ellipsis plans to use new funding to accelerate Sage adoption across healthcare providers, payers, and care management organizations, enhance its AI capabilities, and deepen integration with clinical systems. The company was founded and is led by CEO Mainul Mondal. Financially, Ellipsis has secured a $45M Series A to support these product and go-to-market initiatives. Ellipsis Health, based in San Francisco, develops an AI-powered speech-based vital sign to quantify and manage stress, depression, and anxiety at scale. Its integrated behavioral health solution uses machine-learning algorithms and cloud-based deep learning models to assess patient speech and generate automated assessments for clinical decision support. The company helps healthcare providers and payers identify and stratify patient populations. Ellipsis intends to use the new funding to grow its customer base, expand global partnerships, build a multidisciplinary team, and continue research and development of voice-based technology. It also plans to expand its voice vital sign to address the mental health of children and adolescents. Financially, the company raised a $26M Series A that brought total funding to $31M.

Participated · Seed · Jun 2021

Molecule.one builds an AI-powered synthesis-planning platform that predicts step-by-step routes to make theoretical drug compounds from off-the-shelf chemicals. The system leverages machine learning and a large body of reaction knowledge to propose and internally verify plausible, testable synthesis pathways. The platform has been extended to support planning synthesis for thousands of molecules per hour, allowing it to scale alongside AI drug-discovery systems that generate many candidates. Since its public debut the company has acquired customers on annual contracts and reported efficiency gains as the platform matured. Molecule.one also made part of its platform free to eligible researchers working on COVID drug discovery and established collaborations such as with the LambdaZero project at MILA. The company plans to use new funding to expand the team and open new offices in the U.S. and Western Europe.

Led · Convertible Note · Mar 2021

Treos Bio uses computational data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies. Its lead product is PolyPEPI-1018, an off-the-shelf polypeptide immunotherapy for microsatellite stable metastatic colorectal cancer (MSS mCRC), now entering Phase II trials. An earlier Phase I/II study showed PolyPEPI-1018 induced robust antigen-specific T cell responses and durable anti-tumor responses. Proceeds from the financing will fund two upcoming clinical trials assessing PolyPEPI-1018 as an add-on to first-line maintenance therapy and as third-line treatment in MSS mCRC. Treos has completed preclinical development of off-the-shelf PolyPEPI immunotherapies in ovarian, breast, bladder, gastric and lung cancers and melanoma, and is also developing an investigational COVID-19 peptide vaccine, PolyPEPI-SCoV-2. The company launched in February 2017 and previously raised $28 million in a Series A led by shareholders of BXR Group. Treos Bio develops precision cancer immunotherapies paired to companion diagnostics, including its PolyPEPI™ Immunotherapy Cancer Vaccine for colorectal cancer. The company has completed preclinical development of therapeutic vaccines targeting melanoma, lung cancer, breast cancer, glioblastoma, colorectal cancer and leukemia. It uses companion diagnostics to identify patients likely to respond and plans to treat those identified responders. Treos intends to use the new funding to support an early-stage human clinical trial of the PolyPEPI vaccine in colorectal cancer. Based on discussions with the U.S. Food and Drug Administration, the company expected to begin a first-in-man trial in 2017. The company is led by Executive Chairman Dr. Menghis Bairu and Chief Scientific Officer and co-founder Dr. Julianna Lisziewicz. Treos Bio is based in London, UK and Bethesda, MD.